A new approach to suppressing disease-associated RNA activity is gaining momentum in drug discovery as researchers reported advances in predicting and engineering challenging targets. Among the most notable development in the dataset: an AI-driven method aimed at solving drug transporter mutations deemed “impossible” by conventional computation. The work focuses on the PepT1 transporter (SLC15A1), a key gatekeeper for peptide-like drug absorption in the intestine. By using machine learning to restore plausible transporter behavior in silico, the researchers reported a computational rescue of transporter mutations that conventional modeling struggled to reconcile. For translational teams, the broader takeaway is that algorithmic “feasibility rescue” is beginning to translate into candidate prioritization—potentially shortening the loop from sequence uncertainty to formulation and dosing decisions.